Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
October 2018
-
Media ReleaseBreadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
-
Media ReleaseNovartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN studyData published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or…
-
Digital health ecosystem gets a boost with the Novartis Biome
-
Media ReleaseNovartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patientsThere is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of…
-
Media ReleaseSandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challengesDespite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek…
-
Media ReleaseNovartis licenses three novel anti-infective programs to Boston PharmaceuticalsClinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to…
-
Researchers boost understanding of T-cell therapy in blood cancer
Novartis investigators find genetic explanations for why some young patients relapse.
September 2018
-
Media ReleaseNovartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiativesA panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries The 2018 grants support initiatives ranging from training teachers…
-
Media ReleaseNovartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindnessIn the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be…
-
Media ReleaseNew analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMDPre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period …
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastimPositive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
-
Media ReleaseNovartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in EuropeChildren and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in…
Pagination
- ‹ Previous page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- …
- 150
- › Next page